Earnings History Data for ProPhase Labs, Inc. (PRPH) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
ProPhase Labs, Inc.
ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE?, a zinc gluconate glycine product. COLD-EEZE? family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-11-2024 | PM | PRPH | ProPhase Labs, Inc. | 14.10 | -0.35 | -0.31 | -0.30 | ProPhase Labs reports mixed Q3 results; initiates Q424 soft outlook [11/13/2024 9:19 AM] |
0.77 | 0.03 (4.39%) |
0.70 | -0.04 (-5.10%) |
0.66 - 7.48 | 474,713 | 390,000 | 47,746 | ||
|
||||||||||||||||||
| 14-08-2024 | PM | PRPH | ProPhase Labs, Inc. | 48.27 | -0.33 | -0.25 | -0.20 | ProPhase Labs misses Q2 estimates [8/14/2024 8:08 AM] |
2.50 | 0.03 (1.21%) |
2.35 | -0.12 (-4.86%) |
2.35 - 7.48 | 58,124 | 20,000 | 2,065 | ||
| 09-05-2024 | PM | PRPH | ProPhase Labs, Inc. | 91.31 | -0.07 | -0.28 | 0.03 | ProPhase Labs GAAP EPS of -$0.07 beats by $0.21, revenue of $3.63M misses by $6.23M [5/9/2024 8:14 AM] |
5.11 | -0.28 (-5.19%) |
0.0 | 0.0 (0.00%) |
4.05 - 9.94 | 63,663 | 40,000 | 0 | ||
| 15-03-2024 | PM | PRPH | ProPhase Labs | 87.00 | N/A | -0.27 | 0.00 | ProPhase Labs GAAP EPS of -$0.98 misses by $0.24, revenue of $45.2M misses by $6.38M [3/15/2024 8:01 AM] |
5.16 | 0.30 (6.17%) |
4.57 | -0.29 (-5.97%) |
4.05 - 9.94 | 22,194 | 20,000 | 1,556 | ||
| 09-11-2023 | PM | PRPH | ProPhase Labs, Inc. | 77.32 | -0.30 | -0.20 | 0.06 | ProPhase Labs reports Q3 results [11/9/2023 8:07 AM] |
5.02 | 0.29 (6.13%) |
4.50 | -0.23 (-4.86%) |
4.05 - 12.45 | 26,953 | 10,000 | 1,290 | ||
| 10-08-2023 | PM | PRPH | ProPhase Labs, Inc. | 122.34 | -0.20 | -0.14 | 0.40 | ProPhase Labs GAAP EPS of -$0.20 misses by $0.06, revenue of $13.22M misses by $0.92M [8/10/2023 9:19 AM] |
6.32 | -0.66 (-9.47%) |
0.0 | 0.0 (0.00%) |
6.25 - 13.16 | 108,465 | 20,000 | 0 | ||
| 11-05-2023 | PM | 8:00 AM ET (May 11) |
PRPH | ProPhase Labs, Inc. | 149.66 | 0.03 | -0.10 | 0.68 | ProPhase Labs GAAP EPS of $0.03 beats by $0.13, revenue of $19.3M beats by $4.17M [5/11/2023 8:17 AM] |
8.49 | -0.03 (-0.35%) |
9.20 | 0.68 (7.98%) |
6.09 - 15.25 | 160,866 | 120,000 | 19,894 | |
| 28-03-2023 | PM | 8:00 AM ET (Mar 28) |
PRPH | ProPhase Labs, Inc. | 127.32 | -0.08 | 0.02 | 0.44 | ProPhase Labs GAAP EPS of $1.02 misses by $0.10, revenue of $122.65M beats by $1.31M [3/28/2023 8:03 AM] |
8.22 | 0.06 (0.74%) |
0.0 | 0.0 (0.00%) |
6.09 - 15.25 | 45,807 | 60,000 | 0 | |
| 10-11-2022 | PM | 8:00 AM ET (Nov 10) |
PRPH | ProPhase Labs, Inc. | 200.79 | 0.06 | 0.15 | -0.26 | ProPhase Labs GAAP EPS of $0.06 misses by $0.13, revenue of $24.2M beats by $2.77M [11/10/2022 8:07 AM] |
11.25 | -0.59 (-4.98%) |
10.75 | -1.09 (-9.21%) |
5.10 - 15.25 | 209,533 | 90,000 | 12,965 | |
| 11-08-2022 | PM | 8:30 AM ET (Aug 11) |
PRPH | ProPhase Labs, Inc. | 140.54 | 0.40 | 0.12 | -0.09 | ProPhase Labs GAAP EPS of $0.40 beats by $0.24, revenue of $29.09M beats by $5.77M [8/11/2022 8:10 AM] |
3.76 | -0.21 (-5.29%) |
12.00 | 1.31 (12.25%) |
3.68 - 12.42 | 14,481 | 20,000 | 10,629 | |
| 13-05-2022 | PM | 8:30 AM ET (May 13) |
PRPH | ProPhase Labs, Inc. | 104.37 | 0.68 | 0.39 | 0.23 | ProPhase Labs GAAP EPS of $0.81 beats by $0.34, revenue of $47.5M beats by $15.45M [5/13/2022 8:55 AM] |
7.06 | 0.54 (8.28%) |
7.70 | 1.18 (18.10%) |
4.24 - 8.58 | 78,212 | 30,000 | 10,121 | |
|
||||||||||||||||||
| 30-03-2022 | PM | 8:30 AM ET (Mar 30) |
PRPH | ProPhase Labs, Inc. | 113.90 | 0.44 | 0.36 | 0.00 | ProPhase Labs GAAP EPS of $0.68 beats by $0.11, revenue of $45.2M beats by $10.2M [3/30/2022 8:56 AM] |
7.10 | -0.10 (-1.39%) |
7.98 | 0.78 (10.83%) |
4.01 - 7.80 | 96,607 | 20,000 | 5,842 | |
| 12-11-2021 | PM | 8:10 AM ET (Nov 12) |
PRPH | ProPhase Labs, Inc. | 87.29 | -0.26 | 0.07 | -0.05 | ProPhase Labs EPS misses by $0.02, beats on revenue [11/12/2021 8:37 AM] |
5.68 | -0.11 (-1.90%) |
0.0 | 0.0 (0.00%) |
4.20 - 15.28 | 42,391 | 20,000 | 0 | |
| 13-08-2021 | PM | 8:30 AM ET (Aug 13) |
PRPH | ProPhase Labs, Inc. | 101.23 | -0.09 | 0.19 | 0.01 | ProPhase Labs EPS misses by $0.26, misses on revenue [8/13/2021 8:19 AM] |
6.39 | -0.10 (-1.54%) |
6.32 | -0.17 (-2.62%) |
2.23 - 15.28 | 414,010 | 150,000 | 16,555 | |
| 13-05-2021 | AH | 10:50 PM ET (May 13) |
PRPH | ProPhase Labs, Inc. | 84.26 | 0.23 | 0.35 | -0.07 | ProPhase Labs EPS in-line, beats on revenue [5/13/2021 4:55 PM] |
5.76 | 0.20 (3.60%) |
5.87 | 0.31 (5.58%) |
1.20 - 16.04 | 220,542 | 60,000 | 3,225 | |
|
||||||||||||||||||
| 31-03-2021 | AH | 10:50 PM ET (Mar 31) |
PRPH | ProPhase Labs, Inc. | 93.80 | N/A | -0.04 | 0.00 | ProPhase Labs EPS misses by $0.08, misses on revenue [3/31/2021 10:21 AM] |
6.84 | -0.55 (-7.51%) |
6.91 | -0.49 (-6.56%) |
1.20 - 16.04 | 609,518 | 970,000 | 44,376 | |
|
||||||||||||||||||
| 16-11-2020 | PM | PRPH | ProPhase Labs, Inc. | 98.98 | -0.05 | 0.00 | -0.04 | ProPhase Labs reports Q3 results [11/16/2020 8:50 AM] |
7.52 | -1.17 (-13.46%) |
8.50 | -0.19 (-2.19%) |
1.20 - 11.18 | 127,295 | 128,481 | 1,000 | ||
|
|
||||||||||||||||||